- Home
- SAVA vs MAPS Comparison
SAVA vs MAPS Comparison
Compare SAVA & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- MAPS
- Stock Information
- Founded
- SAVA 1998
- MAPS 2008
- Country
- SAVA United States
- MAPS United States
- Employees
- SAVA N/A
- MAPS N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- MAPS Computer Software: Prepackaged Software
- Sector
- SAVA Health Care
- MAPS Technology
- Exchange
- SAVA Nasdaq
- MAPS Nasdaq
- Market Cap
- SAVA 134.2M
- MAPS 119.8M
- IPO Year
- SAVA N/A
- MAPS N/A
- Fundamental
- Price
- SAVA $2.59
- MAPS $1.37
- Analyst Decision
- SAVA Buy
- MAPS Buy
- Analyst Count
- SAVA 3
- MAPS 2
- Target Price
- SAVA $111.50
- MAPS $2.61
- AVG Volume (30 Days)
- SAVA 12.4M
- MAPS 1.0M
- Earning Date
- SAVA 11-07-2024
- MAPS 11-12-2024
- Dividend Yield
- SAVA N/A
- MAPS N/A
- EPS Growth
- SAVA N/A
- MAPS N/A
- EPS
- SAVA N/A
- MAPS N/A
- Revenue
- SAVA N/A
- MAPS $183,311,000.00
- Revenue This Year
- SAVA N/A
- MAPS N/A
- Revenue Next Year
- SAVA N/A
- MAPS $9.09
- P/E Ratio
- SAVA N/A
- MAPS N/A
- Revenue Growth
- SAVA N/A
- MAPS N/A
- 52 Week Low
- SAVA $2.55
- MAPS $0.70
- 52 Week High
- SAVA $42.20
- MAPS $1.49
- Technical
- Relative Strength Index (RSI)
- SAVA 23.06
- MAPS 60.07
- Support Level
- SAVA $2.78
- MAPS $1.07
- Resistance Level
- SAVA $3.28
- MAPS $1.49
- Average True Range (ATR)
- SAVA 0.24
- MAPS 0.12
- MACD
- SAVA 0.40
- MAPS -0.02
- Stochastic Oscillator
- SAVA 4.73
- MAPS 71.43
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.